Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22022981 | 1.00 | EPHX2 (0.50) | EPHX2FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL20030172 | 1.00 | EPHX2 (0.50) | EPHX2FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL22022994 | 1.00 | EPHX2 (0.50) | EPHX2FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL15616007 | 1.00 | EPHX2 (0.50) | EPHX2FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL20030173 | 1.00 | EPHX2 (0.50) | EPHX2FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL20030175 | 1.00 | EPHX2 (0.50) | EPHX2FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL12179827 | 0.96 | FAAH (0.50) | EPHX2FAAHTRPV1LPAR1LPAR2 | |
| SCHEMBL12179809 | 0.96 | FAAH (0.50) | EPHX2FAAHTRPV1LPAR1LPAR2 | |
| SCHEMBL20017981 | 0.96 | FAAH (0.50) | EPHX2FAAHTRPV1LPAR1LPAR2 | |
| SCHEMBL12179849 | 0.96 | FAAH (0.50) | EPHX2FAAHTRPV1LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2871178-B1 | CATIONIC LIPID | KYOWA KIRIN CO LTD (JP) | 2020-12-23 | — | — | EP | disclosed |